Biotech News

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Rocket Pharmaceuticals (RCKT)Rocket PharmaceuticalsFDA / regulatory

CRANBURY, N.J. --(BUSINESS WIRE)--Oct. 7, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its

Related news

RCKTRocket Pharmaceuticals2026-11-12 21:00 EST

Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress

ETONEton Pharmaceuticals2026-10-14 10:50 EST

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

ARWRArrowhead Pharmaceuticals2026-10-07 11:30 EST

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

RCKTRocket Pharmaceuticals2026-10-06 20:12 EST

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

APVOAptevo Therapeutics2026-11-05 13:30 EST

Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML

BCRXBioCryst Pharmaceuticals2026-10-21 11:00 EST

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

EDITEditas Medicine2026-10-08 11:00 EST

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

ABEOAbeona Therapeutics2026-09-18 11:30 EST

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

KPTIKaryopharm Therapeutics2026-11-17 12:30 EST

Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis

ARWRArrowhead Pharmaceuticals2026-09-29 11:30 EST

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Rocket Pharmaceuticals

Gene Therapies for Rare Disease Rocket Pharmaceuticals develops gene therapies for rare hematologic and cardiovascular disorders using lentiviral and adeno-associated-virus vectors. Commercial Hematology Franchise KRESLADI is an ex vivo lentiviral gene therapy approved for severe leukocyte adhesion deficiency type I. It represents...

Recent company news

Stock data

Close
2.11 USD
Market cap
315.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States